Columbia Laboratories to Discuss Third Quarter 2007 Financial Results on November 8, 2007 Conference Call

LIVINGSTON, N.J., Nov 01, 2007 (BUSINESS WIRE) -- CBRX | charts | news | PowerRating -- Columbia Laboratories, Inc. (NASDAQ: CBRX | charts | news | PowerRating) will hold a conference call on November 8, 2007 to discuss financial results of the three- and nine- months period ended September 30, 2007. Robert S. Mills, president and chief executive officer, and James A. Meer, senior vice president, chief financial officer and treasurer of Columbia Laboratories, will host the call. In addition, George W. Creasy, M.D., FACOG, vice president of clinical research, will review data on the effect of PROCHIVE(R) 8% (progesterone gel) in women with a short cervix in mid-pregnancy. The report on these data, entitled "Vaginal Progesterone Is Associated With a Decrease in Risk for Early Preterm Birth and Improved Neonatal Outcome in Women with a Short Cervix," was published in the October issue of Ultrasound in Obstetrics & Gynecology (also known as The White Journal), the official publication of the International Society of Ultrasound in Obstetrics and Gynecology, and is available at:

http://www3.interscience.wiley.com/cgi-bin/jissue/116322920

Access information

Date: Thursday, November 8, 2007 ---------------------------------------------------------------------- Time: 11:00 AM ET ---------------------------------------------------------------------- Dial-in numbers:(800) 347-6109 (U.S. & Canada) or (913) 312-1398 ---------------------------------------------------------------------- Live webcast: www.cbrxir.com, under "Events" ----------------------------------------------------------------------

All participants are encouraged to access the accompanying PowerPoint presentation at www.cbrxir.com, under "Events".

The teleconference replay will be available two hours after completion through Thursday, November 15, 2007 at (888) 203-1112 (U.S. only) or (719) 457-0820. The replay passcode is 5134103. The archived webcast will be available for one year on the Company's investor website, www.cbrxir.com, under "Events."

About Columbia Laboratories

Columbia Laboratories, Inc. is a specialty pharmaceutical company focused on developing and marketing products for the reproductive healthcare and endocrinology markets using its novel bioadhesive drug delivery technology. For more information, please visit www.columbialabs.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements about Columbia Laboratories, Inc.'s expectations regarding the Company's strategic direction, prospects and future results, which statements are indicated by the words "will," "show," "may" and similar expressions. Such forward-looking statements are subject to certain risks and uncertainties; actual results may differ materially from those projected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. Factors that might cause future results to differ include, but are not limited to, the following: the successful marketing of CRINONE(R) 8% (progesterone gel), PROCHIEVE(R) 8% (progesterone gel), PROCHIEVE(R) 4% (progesterone gel), and STRIANT(R) (testosterone buccal tablet) in the U.S.; the timely and successful development of new products, including PROCHIEVE(R) 8% to reduce the risk of preterm birth in women with a short cervix in mid-pregnancy; the timely and successful completion of clinical studies including the planned Phase III study of PROCHIEVE(R) 8% in short cervix patients; the impact of competitive products and pricing; competitive economic and regulatory factors in the pharmaceutical and healthcare industry; general economic conditions; and other risks and uncertainties that may be detailed, from time-to-time, in Columbia's reports filed with the Securities and Exchange Commission. Columbia Laboratories undertakes no obligation to publicly update any forward-looking statements.

SOURCE: Columbia Laboratories, Inc.

Columbia Laboratories, Inc. James A. Meer, 973-486-8860 Senior Vice President, CFO & Treasurer or Investor and Media: Rx Communications, LLC Melody A. Carey, 917-322-2571 Co-President

Morning Coffee with TradingMarkets -- Free Newsletter

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index